An Unexpected Visitor

References 

1. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Resp Crit Care Med. 1997;156:1–25
2. Marras TK, Morris A, Gonzalez LC, Daley CL. Mortality prediction in pulmonary Mycobacterium kansasii infection and human immunodeficiency virus. Am J Respir Crit Care Med. 2004;170:793–798
   • MEDLINE
   • CrossRef
3. Canueto-Quintero J, Caballero-Granado FJ, Herrero-Romero M, et al. Epidemiological, clinical, and prognostic differences between the diseases caused by Mycobacterium kansasii and Mycobacterium tuberculosis in patients infected with human immunodeficiency virus: a multicenter study. Clin Infect Dis. 2003;37:584–590
   • CrossRef
4. Lillo M, Orengo S, Cernoch P, Harris RL. Pulmonary and disseminated infection due to Mycobacterium kansasii: a decade of experience. Rev Infect Dis. 1990;12:760–767
   • MEDLINE
5. Breathnach A, Levell N, Munro C, et al. Cutaneous Mycobacterium kansasii infection: case report and review. Clin Infect Dis. 1995;20:812–817
   • MEDLINE
   • CrossRef
6. Smith MB, Molina CP, Schnadig VJ, et al. Pathologic features of Mycobacterium kansasii infection in patients with acquired immunodeficiency syndrome. Arch Pathol Lab Med. 2003;127:554–560
7. Griffith DE, Brown-Elliott BA, Wallace RJ. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis. 2003;37:1178–1182
   • CrossRef
8. Wallace RJ, Dunbar D, Brown BA, et al. Rifampin-resistant Mycobacterium kansasii. Clin Infect Dis. 1994;18:736–743
   • MEDLINE
   • CrossRef
9. Guna R, Munoz C, Dominguez V, et al. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. J Antimicrob Chemother. 2005;55:950–953
   • MEDLINE
   • CrossRef